PMID- 35621268
OWN - NLM
STAT- MEDLINE
DCOM- 20230119
LR  - 20230207
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 1
DP  - 2023 Jan
TI  - The characteristics and clinical relevance of tumor fusion burden in head and 
      neck squamous cell carcinoma.
PG  - 852-861
LID - 10.1002/cam4.4890 [doi]
AB  - BACKGROUND: Recent studies suggest that tumor fusion burden (TFB) is a hallmark 
      of immune infiltration in prostate cancer, the correlation of TFB with immune 
      microenvironment, and genomic patterns in head and neck squamous cell carcinomas 
      (HNSC) remain largely unclear. METHODS: Gene fusion, genomic, transcriptomic, and 
      clinical data of HNSC patients from the cancer genome atlas (TCGA) database were 
      collected to analyze the correlation of TFB with mutation patterns, tumor immune 
      microenvironment, and survival time in HNSC patients. RESULTS: Human 
      papillomavirus (HPV) (-) patients with low TFB exhibited significantly enhanced 
      CD8+ T cells infiltration and cytolysis activity and increased level of 
      interferon-gamma (IL-gamma), human leukocyte antigen (HLA) class I, and chemokines. 
      Moreover, TFB was positively correlated with TP53 mutation, score of gene copy 
      number, and loss of heterozygosity (LOH), as well as the biological progress of 
      epithelial-mesenchymal transition (EMT), metastasis, and stem cell 
      characteristics. Further analysis revealed that HPV (-) HNSC patients with low 
      TFB have a better prognosis. CONCLUSIONS: Our data revealed the correlation of 
      TFB with tumor immune microenvironment and predictive features for immunotherapy, 
      implying tumors with low TFB may be potential candidates for immunotherapeutic 
      agents. Moreover, the TFB low group had prolonged overall survival (OS) in the 
      HPV (-) HNSC cohort.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - He, Lirui
AU  - He L
AD  - Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, 
      Shenzhen, China.
FAU - Ren, Dandan
AU  - Ren D
AD  - Genecast Biotechnology Co., Ltd, Jiangsu Province, China.
FAU - Lv, Guoqing
AU  - Lv G
AD  - Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, 
      Shenzhen, China.
FAU - Mao, Beibei
AU  - Mao B
AD  - Genecast Biotechnology Co., Ltd, Jiangsu Province, China.
FAU - Wu, Lijia
AU  - Wu L
AD  - Genecast Biotechnology Co., Ltd, Jiangsu Province, China.
FAU - Liu, Xiaoyu
AU  - Liu X
AD  - Department of Oncology, The Second Xiangya Hospital of Central South University, 
      Changsha, Hunan Province, China.
FAU - Gong, Longlong
AU  - Gong L
AUID- ORCID: 0000-0002-5844-6078
AD  - Genecast Biotechnology Co., Ltd, Jiangsu Province, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Oncology, The Second Xiangya Hospital of Central South University, 
      Changsha, Hunan Province, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220527
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Male
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - *Head and Neck Neoplasms/genetics
MH  - *Papillomavirus Infections/complications
MH  - Clinical Relevance
MH  - Gene Expression Profiling
MH  - Tumor Microenvironment/genetics
MH  - Biomarkers, Tumor/genetics
MH  - Prognosis
PMC - PMC9844600
OTO - NOTNLM
OT  - head and neck squamous cell carcinoma
OT  - human papillomavirus
OT  - immune infiltration
OT  - tumor fusion burden
COIS- The authors made no disclosures.
EDAT- 2022/05/28 06:00
MHDA- 2023/01/20 06:00
PMCR- 2022/05/27
CRDT- 2022/05/27 07:53
PHST- 2022/04/01 00:00 [revised]
PHST- 2021/06/10 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2023/01/20 06:00 [medline]
PHST- 2022/05/27 07:53 [entrez]
PHST- 2022/05/27 00:00 [pmc-release]
AID - CAM44890 [pii]
AID - 10.1002/cam4.4890 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Jan;12(1):852-861. doi: 10.1002/cam4.4890. Epub 2022 May 27.